Dataset Information

Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1.

ABSTRACT: Aicardi-Goutières syndrome is an inflammatory disease occurring due to mutations in any of TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR or IFIH1. We report on 374 patients from 299 families with mutations in these seven genes. Most patients conformed to one of two fairly stereotyped clinical profiles; either exhibiting an in utero disease-onset (74 patients; 22.8% of all patients where data were available), or a post-natal presentation, usually within the first year of life (223 patients; 68.6%), characterized by a sub-acute encephalopathy and a loss of previously acquired skills. Other clinically distinct phenotypes were also observed; particularly, bilateral striatal necrosis (13 patients; 3.6%) and non-syndromic spastic paraparesis (12 patients; 3.4%). We recorded 69 deaths (19.3% of patients with follow-up data). Of 285 patients for whom data were available, 210 (73.7%) were profoundly disabled, with no useful motor, speech and intellectual function. Chilblains, glaucoma, hypothyroidism, cardiomyopathy, intracerebral vasculitis, peripheral neuropathy, bowel inflammation and systemic lupus erythematosus were seen frequently enough to be confirmed as real associations with the Aicardi-Goutieres syndrome phenotype. We observed a robust relationship between mutations in all seven genes with increased type I interferon activity in cerebrospinal fluid and serum, and the increased expression of interferon-stimulated gene transcripts in peripheral blood. We recorded a positive correlation between the level of cerebrospinal fluid interferon activity assayed within one year of disease presentation and the degree of subsequent disability. Interferon-stimulated gene transcripts remained high in most patients, indicating an ongoing disease process. On the basis of substantial morbidity and mortality, our data highlight the urgent need to define coherent treatment strategies for the phenotypes associated with mutations in the Aicardi-Goutières syndrome-related genes. Our findings also make it clear that a window of therapeutic opportunity exists relevant to the majority of affected patients and indicate that the assessment of type I interferon activity might serve as a useful biomarker in future clinical trials.

SUBMITTER: Crow YJ

PROVIDER: S-EPMC4382202 | biostudies-literature | 2015 Feb

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1.

Crow Yanick J YJ Chase Diana S DS Lowenstein Schmidt Johanna J Szynkiewicz Marcin M Forte Gabriella M A GM Gornall Hannah L HL Oojageer Anthony A Anderson Beverley B Pizzino Amy A Helman Guy G Abdel-Hamid Mohamed S MS Abdel-Salam Ghada M GM Ackroyd Sam S Aeby Alec A Agosta Guillermo G Albin Catherine C Allon-Shalev Stavit S Arellano Montse M Ariaudo Giada G Aswani Vijay V Babul-Hirji Riyana R Baildam Eileen M EM Bahi-Buisson Nadia N Bailey Kathryn M KM Barnerias Christine C Barth Magalie M Battini Roberta R Beresford Michael W MW Bernard Geneviève G Bianchi Marika M Billette de Villemeur Thierry T Blair Edward M EM Bloom Miriam M Burlina Alberto B AB Carpanelli Maria Luisa ML Carvalho Daniel R DR Castro-Gago Manuel M Cavallini Anna A Cereda Cristina C Chandler Kate E KE Chitayat David A DA Collins Abigail E AE Sierra Corcoles Concepcion C Cordeiro Nuno J V NJ Crichiutti Giovanni G Dabydeen Lyvia L Dale Russell C RC D'Arrigo Stefano S De Goede Christian G E L CG De Laet Corinne C De Waele Liesbeth M H LM Denzler Ines I Desguerre Isabelle I Devriendt Koenraad K Di Rocco Maja M Fahey Michael C MC Fazzi Elisa E Ferrie Colin D CD Figueiredo António A Gener Blanca B Goizet Cyril C Gowrinathan Nirmala R NR Gowrishankar Kalpana K Hanrahan Donncha D Isidor Bertrand B Kara Bülent B Khan Nasaim N King Mary D MD Kirk Edwin P EP Kumar Ram R Lagae Lieven L Landrieu Pierre P Lauffer Heinz H Laugel Vincent V La Piana Roberta R Lim Ming J MJ Lin Jean-Pierre S-M JP Linnankivi Tarja T Mackay Mark T MT Marom Daphna R DR Marques Lourenço Charles C McKee Shane A SA Moroni Isabella I Morton Jenny E V JE Moutard Marie-Laure ML Murray Kevin K Nabbout Rima R Nampoothiri Sheela S Nunez-Enamorado Noemi N Oades Patrick J PJ Olivieri Ivana I Ostergaard John R JR Pérez-Dueñas Belén B Prendiville Julie S JS Ramesh Venkateswaran V Rasmussen Magnhild M Régal Luc L Ricci Federica F Rio Marlène M Rodriguez Diana D Roubertie Agathe A Salvatici Elisabetta E Segers Karin A KA Sinha Gyanranjan P GP Soler Doriette D Spiegel Ronen R Stödberg Tommy I TI Straussberg Rachel R Swoboda Kathryn J KJ Suri Mohnish M Tacke Uta U Tan Tiong Y TY te Water Naude Johann J Wee Teik Keng K Thomas Maya Mary MM Till Marianne M Tonduti Davide D Valente Enza Maria EM Van Coster Rudy Noel RN van der Knaap Marjo S MS Vassallo Grace G Vijzelaar Raymon R Vogt Julie J Wallace Geoffrey B GB Wassmer Evangeline E Webb Hannah J HJ Whitehouse William P WP Whitney Robyn N RN Zaki Maha S MS Zuberi Sameer M SM Livingston John H JH Rozenberg Flore F Lebon Pierre P Vanderver Adeline A Orcesi Simona S Rice Gillian I GI

American journal of medical genetics. Part A 20150116 2

Aicardi-Goutières syndrome is an inflammatory disease occurring due to mutations in any of TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR or IFIH1. We report on 374 patients from 299 families with mutations in these seven genes. Most patients conformed to one of two fairly stereotyped clinical profiles; either exhibiting an in utero disease-onset (74 patients; 22.8% of all patients where data were available), or a post-natal presentation, usually within the first year of life (223 patients; 6 ...[more]

PMID: 25604658

Similar Datasets

Project description:Mutations in presenilin 2 are rare causes of early onset familial Alzheimer's disease. Eighteen presenilin 2 mutations have been reported, although not all have been confirmed pathogenic. Much remains to be learned about the range of phenotypes associated with these mutations. We have analysed our unique collection of 146 affected cases in 11 Volga German families, 101 who are likely to have the same N141I mutation in presenilin 2 (54 genotyped confirmed). We have also assessed the detailed neuropathologic findings in 18 autopsies from these families and reviewed the world's literature on other presenilin 2 mutations; presenting a novel mutation that is predicted to lead to a premature truncation codon. Seven presenilin 2 mutations reported in the literature have strong evidence for pathogenicity whereas others may be benign polymorphisms. One hundred and one affected persons, with sufficient historical information from the Volga German pedigrees (N141I mutation), had a mean onset age of 53.7 years+/-7.8 (range 39-75) and mean age at death of 64.2 years+/-9.8 (range 43-88). These figures overlap with and generally fall between the results from the subjects in our centre who have late onset familial Alzheimer's disease or mutations in presenilin 1. Seizures were noted in 20 (30%) of 64 subjects with detailed medical records. Two mutation carriers lived beyond age 80 without developing dementia, representing uncommon examples of decreased penetrance. Two persons had severe amyloid angiopathy and haemorrhagic stroke. Eighteen cases had detailed histopathology available and analysed at our institution. Braak stage was five or six, amyloid angiopathy and neuritic plaques were common and more than 75% had Lewy bodies in the amygdala. TAR DNA-binding protein-43 inclusions were uncommon. In addition, a 58-year-old female with a 2 year course of cognitive decline and no family history of dementia has abnormal fludeoxyglucose-positron emission tomography imaging and a novel 2 base pair deletion in presenilin 2 at nucleotide 342/343, predicted to produce a frame-shift and premature termination. We conclude that mutations in presenilin 2 are rare with only seven being well documented in the literature. The best studied N141I mutation produces an Alzheimer's disease phenotype with a wide range of onset ages overlapping both early and late onset Alzheimer's disease, often associated with seizures, high penetrance and typical Alzheimer's disease neuropathology. A novel premature termination mutation supports loss of function or haploinsufficiency as pathogenic mechanisms in presenilin 2 associated Alzheimer's disease.

Dataset Information

Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1.

Publications

Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure